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Fertility and Sterility®Main Results and the Role of Chance: The evidence in the assessment and management of PCOS is generally of low to moderate
quality. The guideline provides 31 evidence based recommendations, 59 clinical consensus recommendations and 76 clinical practice
points all related to assessment and management of PCOS. Key changes in this guideline include: i) considerable reﬁnement of
individual diagnostic criteria with a focus on improving accuracy of diagnosis; ii) reducing unnecessary testing; iii) increasing focus
on education, lifestyle modiﬁcation, emotional wellbeing and quality of life; and iv) emphasizing evidence based medical therapy
and cheaper and safer fertility management.
Limitations, Reasons for Caution: Overall evidence is generally low tomoderate quality, requiring signiﬁcantly greater research in this
neglected, yet common condition, especially around reﬁning speciﬁc diagnostic features in PCOS. Regional health system variation is
acknowledged and a process for guideline and translation resource adaptation is provided.
Wider Implications of the Findings: The international guideline for the assessment and management of PCOS provides clinicians with
clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research
recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the
guideline with an integrated evaluation program.
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Polycystic ovary syndrome (PCOS) is the most common endo-
crinopathy affecting reproductive aged women, with a preva-
lence of between 8% and 13% depending on the population
studied and deﬁnitions used (1, 2). PCOS is complex with
reproductive, metabolic and psychological features (1, 2).
Clinical practice in the assessment and management of PCOS
is inconsistent, with key evidence practice gaps, whilst
women internationally have highlighted delayed diagnosis
and dissatisfaction with care (3-5). Current guidelines either
are limited in breadth, do not follow rigorous best practice in
development, have not involved consumers, or are outdated
(6-10), resulting in inconsistent guidance for clinicians and
women alike. To address these identiﬁed gaps, here we
summarize the development process and recommendations
from the ﬁrst international evidence-based guideline for the
assessment and management of PCOS, bringing together
extensive consumer engagement and international collabora-
tionwith leading societies and organizations, multidisciplinary
experts, and primary care representatives. In this process, the
guideline development groups unanimously supported the Rot-
terdam diagnostic criteria for adult women.
This comprehensive evidence-based guideline builds on
prior high quality guidelines and culminates from a rigorous,
Appraisal of Guidelines for Research and Evaluation-II
(AGREEII)-compliant, evidence-based guideline development
process. It provides a single source of international evidence-
based recommendations to guide clinical practice with the op-
portunity for adaptation in relevant health systems. Together
with an extensive translation program, the aim is to reduceVOL. 110 NO. 3 / AUGUST 2018worldwide variation in care and promote high quality service
provision to improve health outcomes and quality of life in
women with PCOS. The guidelines are supported by a multifac-
eted international translation program with co-designed re-
sources to enhance the skills of health professionals and
empower women with PCOS, with an integrated comprehensive
evaluation program.WHAT DOES THIS MEAN FOR ADOLESCENTS
AND WOMEN WITH PCOS?
This guideline aims to optimize evidence-based, consistent
care that meets the needs and improves the quality of life of
women with PCOS. The guideline and translation program
were developed with full consumer participation at all stages,
targeting areas and outcomes of priority for women with
PCOS. The aim is to support women and their health care pro-
viders to optimize diagnosis, assessment and management of
PCOS. There is an emphasis on partnership in care and
empowerment of women with PCOS. Personal characteristics,
preferences, culture and values are considered. With effective
translation, the guideline and health professional and con-
sumer resources will address gaps and priorities identiﬁed
by women with PCOS and will promote vital future research.MATERIALS AND METHODS
Best practice evidence-based guideline development methods
were applied and are detailed in the full guideline and the
technical reports and outlined in Figure 1 and available at
https://www.monash.edu/medicine/sphpm/mchri/pcos (11).365
FIGURE 1
The steps in developing an evidence-based guideline. GDG ¼ guideline development group; PICO ¼ P, patient, problem or population; I,
intervention; C, comparison, control or comparator; O, outcome. Reprinted with permissions from Misso and Teede (11).
Teede. International evidence-based guideline. Fertil Steril 2018.
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quality guideline assessment (12). This involved extensive
evidence synthesis and the Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE) frame-
work covering evidence quality, feasibility, acceptability,
cost, implementation, and ultimately recommendation
strength (13). Evidence synthesis methods are outlined in
the full guideline and followed best practice (12-15).
Categories include evidence-based or consensus recommen-
dations with accompanying clinical practice points (Table 1).
Terms include ‘‘should,’’ ‘‘could,’’ and ‘‘should not,’’ are
informed by the nature of the recommendation (evidence or
consensus), the GRADE framework and quality of the
evidence and are independent descriptors reﬂecting the
judgement of the multidisciplinary guideline development
group (GDG), including consumers. They refer to overall
interpretation and practical application of the recommenda-
tion, balancing beneﬁts and harms. ‘‘Should’’ is used where
beneﬁts of the recommendation exceed harms, and where
the recommendation can be trusted to guide practice. ‘‘Could’’
is used where either the quality of evidence was limited or theTABLE 1
Categories of recommendations in the PCOS guideline.
EBR Evidence-based recommendations are made where evidence is
development group.
CCR Clinical consensus recommendations are made in the absence o
populations and are made by the guideline development g
CPP Clinical practice points are madewhere evidencewas not sough
evidence-based or clinical consensus recommendations.
Teede. International evidence-based guideline. Fertil Steril 2018.
366available studies demonstrate little clear advantage of one
approach over another, or the balance of beneﬁts to harm
was unclear. ‘‘Should not’’ is used where there is either a
lack of appropriate evidence, or the harms may outweigh
the beneﬁts.
The GRADE of the recommendation is determined by
the guideline development group based on comprehensive
structured consideration of all elements of the GRADE
framework (4), including desirable effects, undesirable
effects, balance of effects, resource requirements and
cost effectiveness, equity, acceptability and feasibility and
includes:
* Conditional recommendation against the option;
** Conditional recommendation for either the option or the
comparison;
*** Conditional recommendation for the option;
**** Strong recommendation for the option.
Quality of the evidence is categorized according to: the
number and design of studies addressing the outcome;
judgments about the quality of the studies and/or synthesizedsufﬁcient to inform a recommendation made by the guideline
f adequate evidence on PCOS. These are informed by evidence in other
roup, using rigorous and transparent processes.
t and are madewhere important clinical issues arose from discussion of
VOL. 110 NO. 3 / AUGUST 2018
TABLE 2
Quality (certainty) of evidence categories
High 4444 Very conﬁdent that the true effect lies close to that of the estimate of the effect.
Moderate 444B Moderate conﬁdence in the effect estimate: the true effect is likely to be close to the estimate of the effect, but
there is a possibility that it is substantially different.
Low 44BB Limited conﬁdence in the effect estimate: the true effect may be substantially different from the estimate of the
effect.
Very Low 4BBB Very little conﬁdence in the effect estimate: the true effect is likely to be substantially different from the estimate
of effect.
Note: Adapted from the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) (13).
Teede. International evidence-based guideline. Fertil Steril 2018.
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cision, and any other considerations that may inﬂuence the
quality of the evidence; key statistical data; and classiﬁcation
of the importance of the outcomes (Table 2). The quality of evi-
dence reﬂects the extent of conﬁdence in an estimate of the ef-
fect to support a particular recommendation (4) and was largely
determined by the expert evidence synthesis team.
GRADE acknowledges that evidence quality is a contin-
uum; any discrete categorization involves a degree of arbitrar-
iness. Nevertheless, the advantages of simplicity,
transparency, and clarity outweigh these limitations (4).
RESULTS
The recommendation table (Table 3) applies the category,
descriptive terms, GRADE of the recommendations and the
quality of the evidence. The full guideline is available at
https://www.monash.edu/medicine/sphpm/mchri/pcos. The
full version of the guideline outlines the clinical need for
the question, the clinical question, the evidence summary,
the recommendation and practice points and a summary of
the justiﬁcation developed by the GDGs using the GRADE
framework, reﬁned by extensive international peer review.
The comprehensive evidence reviews, proﬁles and GRADE
frameworks supporting each recommendation, can be found
at https://www.monash.edu/medicine/sphpm/mchri/pcos in
the Supplementary Technical Reports. The peer review feed-
back, administrative report on guideline development and
disclosure of interest process and declarations can be found
at https://www.monash.edu/medicine/sphpm/mchri/pcos.
Here we present the clinical topic area recommendations
and practice points (Table 3). This summary, the full guideline
and technical reports are supported by a comprehensive co-
designed translation program to optimize dissemination and
impact with resources freely available at https://www.mona-
sh.edu/medicine/sphpm/mchri/pcos.
DISCUSSION
The International Guideline for the Assessment and Manage-
ment of PCOS and the related translation program aims to pro-
vide clinicians with a quality, reliable source of international
evidence-based recommendations to guide consistent clinical
practice and to empower women with evidence-based infor-
mation. All recommendations were formulated after an assess-
ment of the best available evidence, multidisciplinary clinical
expertise, consumer preferences and structured review by the
ﬁve GDGs. Detailed methods for stakeholder engagementVOL. 110 NO. 3 / AUGUST 2018and guideline development can be found at https://www.mo-
nash.edu/medicine/sphpm/mchri/pcos. The guideline provides
166 recommendations: evidence-based recommendations
(EBR) ¼ 31, clinical consensus recommendations (CCR) ¼ 59,
and clinical practice points (CPP) ¼ 76. Overall evidence is of
low to moderate quality, requiring signiﬁcant research expan-
sion in this neglected, yet common condition.
We endorse the Rotterdam PCOS Diagnostic Criteria
in adults (two of oligo- or anovulation, clinical and/or
biochemical hyperandrogenism, or polycystic ovaries on ul-
trasound), after exclusion of related disorders. Where both
oligo- or anovulation and hyperandrogenism are present, ul-
trasound is not necessary for diagnosis. In adolescents, both
oligo-anovulation and hyperandrogenism are required, with
ultrasound not recommended for diagnosis. Ultrasound
criteria are reﬁned with advancing technology. Antim€uller-
ian hormone levels are not yet adequate for diagnosis of
PCOS. Insulin resistance is recognized as a key feature of
PCOS, yet clinical measurement is not recommended at the
current time. Once diagnosed, assessment and management
includes reproductive, metabolic, and psychological features.
Education, self-empowerment, multidisciplinary care, and
lifestyle intervention for prevention or management of
excess weight are prioritized. Depressive and anxiety symp-
toms should be screened, assessed, and managed and health
professionals should be aware of other impacts on emotional
wellbeing and quality of life. Combined oral contraceptive
pills are ﬁrst-line pharmacological management for men-
strual irregularity and hyperandrogenism, with no speciﬁc
formulation recommended and with low-dose preparations
preferred. Metformin is recommended in addition or alone,
primarily for management of metabolic features. Letrozole
is ﬁrst-line pharmacological infertility therapy; with clomi-
phene and metformin both having a role, alone and in com-
bination. In women with PCOS and anovulatory infertility,
gonadotrophins are second line. In the absence of an abso-
lute indication for IVF, women with PCOS and anovulatory
infertility could be offered IVF third line where other ovula-
tion induction therapies have failed.
The combined effects of the provision of a single source
of evidence-based recommendations and a comprehensive
international translation and dissemination program will
amplify the impact of the guideline and recommendations
globally. It will support and build the capability of health
professionals to deliver high-quality, evidence-based
assessment and management of PCOS and will augment
the health literacy and self-management of PCOS health367
TABLE 3
Recommendations and practice points.
Category (see Table 1
for deﬁnition) Recommendation
GRADE and
Quality
1. SCREENING, DIAGNOSTIC ASSESSMENT, RISK ASSESSMENT, AND LIFE-STAGE
Irregular cycles and ovulatory dysfunction
CCR Irregular menstrual cycles are deﬁned as:
 Normal in the ﬁrst year post menarche as part of the pubertal transition
 1 to < 3 years post menarche: < 21 or > 45 days
 3 years post menarche to perimenopause: < 21 or > 35 days or < 8 cycles per year
 1 year post menarche > 90 days for any one cycle
 Primary amenorrhea by age 15 or > 3 years post thelarche (breast development)
When irregular menstrual cycles are present a diagnosis of PCOS should be considered and assessed
according to the guidelines
****
CCR In an adolescent with irregular menstrual cycles, the value and optimal timing of assessment and
diagnosis of PCOS should be discussed with the patient, taking into account diagnostic challenges
at this life stage and psychosocial and cultural factors
****
CPP For adolescents who have features of PCOS but do not meet diagnostic criteria, an ‘‘increased risk’’
could be considered and reassessment advised at or before full reproductive maturity, 8 years post
menarche. This includes those with PCOS features before combined oral contraceptive pill (COCP)
commencement, those with persisting features and those with signiﬁcant weight gain in
adolescence.
CPP Ovulatory dysfunction can still occur with regular cycles and if anovulation needs to be conﬁrmed
serum progesterone levels can be measured.
_
Biochemical hyperandrogenism
EBR Calculated free testosterone, free androgen index, or calculated bioavailable testosterone should be
used to assess biochemical hyperandrogenism in the diagnosis of PCOS.
****
44BB
EBR High quality assays such as liquid chromatography–mass spectrometry (LCMS) and extraction/
chromatography immunoassays, should be used for the most accurate assessment of total or free
testosterone in PCOS.
***
44BB
EBR Androstenedione and dehydroepiandrosterone sulfate (DHEAS) could be considered if total or free
testosterone are not elevated; however, these provide limited additional information in the
diagnosis of PCOS.
***
44BB
CCR Direct free testosterone assays, such as radiometric or enzyme-linked assays, preferably should not be
used in assessment of biochemical hyperandrogenism in PCOS, as they demonstrate poor
sensitivity, accuracy and precision.
CPP Reliable assessment of biochemical hyperandrogenism is not possible in women on hormonal
contraception, due to effects on sex hormone-binding globulin and altered gonadotrophin-
dependent androgen production.
_
CPP Where assessment of biochemical hyperandrogenism is important in women on hormonal
contraception, drugwithdrawal is recommended for threemonths or longer beforemeasurement,
and contraception management with a non-hormonal alternative is needed during this time.
_
CPP Assessment of biochemical hyperandrogenism is most useful in establishing the diagnosis of PCOS
and/or phenotype where clinical signs of hyperandrogenism (in particular hirsutism) are unclear or
absent.
_
CPP Interpretation of androgen levels needs to be guided by the reference ranges of the laboratory used,
acknowledging that ranges for different methods and laboratories vary widely. Normal values are
ideally based on levels from awell phenotyped healthy control population or by cluster analysis of a
large general population considering age and pubertal speciﬁc stages.
_
CPP Where androgen levels are markedly above laboratory reference ranges, other causes of biochemical
hyperandrogenism need to be considered. History of symptom onset and progression is critical in
assessing for neoplasia, however, some androgen-secreting neoplasms may only induce mild to
moderate increases in biochemical hyperandrogenism.
_
Clinical hyperandrogenism
CCR A comprehensive history and physical examination should be completed for symptoms and signs of
clinical hyperandrogenism, including acne, alopecia, and hirsutism and, in adolescents, severe
acne and hirsutism.
****
CCR Health professionals should be aware of the potential negative psychosocial impact of clinical
hyperandrogenism. Reported unwanted excess hair growth and/or alopecia should be considered
important, regardless of apparent clinical severity.
****
CCR Standardized visual scales are preferred when assessing hirsutism, such as the modiﬁed Ferriman
Gallwey score (mFG) with a levelR 4-6 indicating hirsutism, depending on ethnicity,
acknowledging that self-treatment is common and can limit clinical assessment. (See
recommendations on ethnic variation.)
****
CCR The Ludwig visual score is preferred for assessing the degree and distribution of alopecia. ****
CPP There are no universally accepted visual assessments for evaluating acne.
CPP The prevalence of hirsutism is the same across ethnicities, yet the mFG cut-off scores for deﬁning
hirsutism and the severity of hirsutism varies by ethnicity.
_
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GRADE and
Quality
CPP As ethnic variation in vellus hair density is notable, over-estimation of hirsutismmay occur if vellus hair
is confused with terminal hair; only terminal hairs need to be considered in pathological hirsutism,
with terminal hairs clinically growing > 5 mm in length if untreated, varying in shape and texture
and generally being pigmented.
_
Ultrasound and polycystic ovarian morphology (PCOM)
CCR Ultrasound should not be used for the diagnosis of PCOS in thosewith a gynecological age of<8 years
(<8 years after menarche), due to the high incidence of multi-follicular ovaries in this life stage.
****
CCR The threshold for PCOM should be revised regularly with advancing ultrasound technology, and age-
speciﬁc cut off values for PCOM should be deﬁned.
****
CCR The transvaginal ultrasound approach is preferred in the diagnosis of PCOS, if sexually active and if
acceptable to the individual being assessed.
****
CCR Using endovaginal ultrasound transducers with a frequency bandwidth that includes 8 MHz, the
threshold for PCOM on either ovary, a follicle number per ovary ofR20 and/or an ovarian volume
R 10 ml on either ovary, ensuring no corpora lutea, cysts or dominant follicles are present.
***
CPP If using older technology, the threshold for PCOM could be an ovarian volumeR 10 ml on either
ovary.
_
CPP In patients with irregular menstrual cycles and hyperandrogenism, an ovarian ultrasound is not
necessary for PCOS diagnosis; however, ultrasound will identify the complete PCOS phenotype.
_
CPP In transabdominal ultrasound reporting is best focused on ovarian volume with a threshold ofR
10 ml, given the difﬁculty of reliably assessing follicle number with this approach.
_
CPP Clear protocols are recommended for reporting follicle number per ovary and ovarian volume on ul-
trasound. Recommended minimum reporting standards include:
 Last menstrual period
 Transducer bandwidth frequency
 Approach/route assessed
 Total follicle number per ovary measuring 2-9 mm
 Three dimensions and volume of each ovary
 Reporting of endometrial thickness and appearance is preferred; 3-layer endometrial
assessment may be useful to screen for endometrial pathology
 Other ovarian and uterine pathology, as well as ovarian cysts, corpus luteum, dominant follicles
R 10 mm
_
CPP There is a need for training in careful and meticulous follicle counting per ovary, to improve reporting. _
Anti-m€ullerian hormone (AMH)
EBR SerumAMH levels should not yet be used as an alternative for the detection of PCOMor as a single test
for the diagnosis of PCOS.
***
44BB
CPP There is emerging evidence that with improved standardization of assays and established cut off levels
or thresholds based on large scale validation in populations of different ages and ethnicities, AMH
assays will be more accurate in the detection of PCOM.
_
Ethnic variation
CCR Health professionals should consider ethnic variation in the presentation and manifestations of PCOS,
including:
 A relatively mild phenotype in Caucasians
 Higher body mass index (BMI) in Caucasian women, especially in North America and Australia
 More severe hirsutism in Middle Eastern, Hispanic, and Mediterranean women
 Increased central adiposity, insulin resistance, diabetes, metabolic risks, and acanthosis nigricans
in South East Asians and Indigenous Australians
 Lower BMI and milder hirsutism in East Asians
 Higher BMI and metabolic features in Africans
****
Menopause life stage
CCR Postmenopausal persistence of PCOS could be considered likely with continuing evidence of
hyperandrogenism.
***
CCR A diagnosis of PCOS postmenopause could be considered if there is a past diagnosis of PCOS, a long-
term history of irregular menstrual cycles and hyperandrogenism and/or PCOM, during the
reproductive years.
***
CPP Postmenopausal women presenting with new-onset, severe or worsening hyperandrogenism
including hirsutism, require investigation to rule out androgen-secreting tumors and ovarian
hyperthecosis.
_
Cardiovascular disease risk (CVD)
CCR All those with PCOS should be offered regular monitoring for weight changes and excess weight, in
consultationwith andwhere acceptable to the individual woman.Monitoring could be at each visit
****
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or at a minimum 6-12 monthly, with frequency planned and agreed between the health
professional and the individual.
CCR Weight, height, and ideally waist circumference should be measured and BMI calculated with the
following considered:
 BMI categories and waist circumference should follow World Health Organization guidelines,
also noting ethnic and adolescent ranges.
 Consideration should be given for Asian and high-risk ethnic groups including recommended
monitoring of waist circumference.
****
CCR All women with PCOS should be assessed for cardiovascular risk factors and global CVD risk. ****
CCR If screening reveals CVD risk factors including obesity, cigarette smoking, dyslipidemia, hypertension,
impaired glucose tolerance, and lack of physical activity, women with PCOS should be considered
at increased risk of CVD.
****
CCR Overweight and obese women with PCOS, regardless of age, should have a fasting lipid proﬁle
(cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol and
triglyceride level at diagnosis). Thereafter, frequency of measurement should be based on the
presence of hyperlipidemia and global CVD risk.
****
CCR All women with PCOS should have blood pressure measured annually, or more frequently based on
global CVD risk.
****
CPP Health professionals need to be aware that CVD risk in women with PCOS remains unclear pending
high quality studies, however prevalence of CVD risk factors is increased, warranting consideration
of screening.
_
CPP Consideration needs to be given to the signiﬁcant differences in CVD risk across ethnicities (See Ethnic
variation) when determining frequency of risk assessment.
_
Gestational diabetes, impaired glucose tolerance and type 2 diabetes
CCR Health professionals andwomenwith PCOS should be aware that, regardless of age, the prevalence of
gestational diabetes, impaired glucose tolerance and type 2 diabetes (5-fold in Asia, 4-fold in the
Americas, and 3-fold in Europe) are signiﬁcantly increased in PCOS, with risk independent of, yet
exacerbated by, obesity.
****
CCR Glycemic status should be assessed at baseline in all womenwith PCOS. Thereafter, assessment should
be every one to three years, inﬂuenced by the presence of other diabetes risk factors.
****
CCR An oral glucose tolerance test (OGTT), fasting plasma glucose or HbA1c should be performed to assess
glycemic status. In high-risk women with PCOS (including a BMI > 25 kg/m2 or in Asians> 23 kg/
m2, history of impaired fasting glucose, impaired glucose tolerance or gestational diabetes, family
history of diabetes mellitus type 2, hypertension or high-risk ethnicity), an OGTT is recommended.
****
CCR A 75-g OGTT should be offered in all women with PCOS preconception when planning pregnancy or
seeking fertility treatment, given the high risk of hyperglycemia and the associated comorbidities in
pregnancy. If not performed preconception, an OGTT should be offered at < 20 weeks gestation,
and all women with PCOS should be offered the test at 24-28 weeks gestation.
****
Obstructive sleep apnea (OSA)
CCR Screening should only be considered for OSA in PCOS to identify and alleviate related symptoms, such
as snoring, waking unrefreshed from sleep, daytime sleepiness, and the potential for fatigue to
contribute to mood disorders. Screening should not be considered with the intention of improving
cardiometabolic risk, with inadequate evidence for metabolic beneﬁts of OSA treatment in PCOS
and in general populations.
****
CCR A simple screening questionnaire, preferably the Berlin tool, could be applied and if positive, referral to
a specialist considered.
***
CPP A positive screen raises the likelihood of OSA, however it does not quantify symptom burden and
alone does not justify treatment. If women with PCOS have OSA symptoms and a positive screen,
consideration can be given to referral to a specialist center for further evaluation.
_
Endometrial cancer
CCR Health professionals and women with PCOS should be aware of a 2- to 6-fold increased risk of
endometrial cancer, which often presents before menopause; however absolute risk of
endometrial cancer remains relatively low.
***
CPP Health professionals require a low threshold for investigation of endometrial cancer in women with
PCOS or a history of PCOS, with investigation by transvaginal ultrasound and/or endometrial
biopsy recommended with persistent thickened endometrium and/or risk factors including
prolonged amenorrhea, abnormal vaginal bleeding or excess weight. However, routine ultrasound
screening of endometrial thickness in PCOS is not recommended.
_
CPP Optimal prevention for endometrial hyperplasia and endometrial cancer is not known. A pragmatic
approach could include COCP or progestin therapy in those with cycles longer than 90 days.
_
2. PREVALENCE, SCREENING, DIAGNOSTIC ASSESSMENT AND TREATMENT IN EMOTIONAL WELLBEING
Quality of life
CCR Health professionals and women should be aware of the adverse impact of PCOS on quality of life. ****
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CCR Health professionals should capture and consider perceptions of symptoms, impact on quality of life
and personal priorities for care to improve patient outcomes.
****
CPP The PCOS quality of life tool (PCOSQ), or the modiﬁed PCOSQ, may be useful clinically to highlight
PCOS features causing greatest distress, and to evaluate treatment outcomes on women's
subjective PCOS health concerns.
_
Depressive and anxiety symptoms, screening and treatment
CCR Health professionals should be aware that in PCOS, there is a high prevalence of moderate to severe
anxiety and depressive symptoms in adults; and a likely increased prevalence in adolescents.
****
CCR Anxiety and depressive symptoms should be routinely screened in all adolescents and women with
PCOS at diagnosis. If the screen for these symptoms and/or other aspects of emotional wellbeing is
positive, further assessment and/or referral for assessment and treatment should be completed by
suitably qualiﬁed health professionals, informed by regional guidelines.
****
CCR If treatment is warranted, psychological therapy and/or pharmacological treatment should be offered
in PCOS, informed by regional clinical practice guidelines.
****
CPP The optimal interval for anxiety and depressive symptom screening is not known. A pragmatic
approach could include repeat screening using clinical judgment, considering risk factors,
comorbidities and life events.
_
CPP Assessment of anxiety and or depressive symptoms involves assessment of risk factors, symptoms and
severity. Symptoms can be screened according to regional guidelines, or by using simple stepwise
approaches (see full guideline for details).
_
CPP Where pharmacological treatment for anxiety and depression is offered in PCOS, the following need
consideration:
 Caution is needed to avoid inappropriate treatment with antidepressants or anxiolytics. Where
mental health disorders are clearly documented and persistent, or if suicidal symptoms are
present, treatment of depression or anxiety need to be informed by clinical regional practice
guidelines.
 Use of agents that exacerbate PCOS symptoms, including weight gain, need careful
consideration.
_
CPP Factors including obesity, infertility, and hirsutism need consideration along with use of hormonal
medications in PCOS, as theymay independently exacerbate depressive and anxiety symptoms and
other aspects of emotional wellbeing.
_
Psychosexual function
CCR All health professionals should be aware of the increased prevalence of psychosexual dysfunction and
should consider exploring how features of PCOS, including hirsutism and body image, impact on
sex life and relationships in PCOS.
****
CCR If psychosexual dysfunction is suspected, tools such as the Female Sexual Function Index can be
considered.
****
Body Image
CCR Health professionals and women should be aware that features of PCOS can impact on body image. ***
CPP Negative body image, can be screened according to regional guidelines or by using a stepped
approach (see full guideline for details.
_
Eating disorders and disordered eating
CCR All health professionals and women should be aware of the increased prevalence of eating disorders
and disordered eating associated with PCOS.
**
CCR If eating disorders and disordered eating are suspected, further assessment, referral and treatment,
including psychological therapy, could be offered by appropriately trained health professionals,
informed by regional guidelines or by using a stepped approach (see full guideline for details).
**
Information resources, models of care, cultural and linguistic considerations
CCR Information and education resources for women with PCOS should be culturally appropriate, tailored
and high-quality, should use a respectful and empathetic approach, and promote self-care and
highlight peer support groups.
****
CCR Information and education resources for healthcare professionals should promote the recommended
diagnostic criteria, appropriate screening for comorbidities, and effective lifestyle and
pharmacological management.
****
CCR PCOS information should be comprehensive, evidence-based, and inclusive of the biopsychosocial
dimensions of PCOS across the life-span.
****
CCR Women's needs, communication preferences, beliefs, and culture should be considered and
addressed through provision of culturally and linguistically appropriate co-designed resources and
care.
****
CPP Interdisciplinary care needs to be considered for those with PCOS where appropriate and available.
Primary care is generally well placed to diagnose, screen and coordinate interdisciplinary care.
_
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CPP Care needs to be person centered, address women's priorities and be provided in partnership with
those with PCOS and where appropriate, their families.
_
CPP Guideline dissemination and translation including multimodal education tools and resources is
important, with consultation and engagement with stakeholders internationally.
_
3. LIFESTYLE
Effectiveness of lifestyle interventions
CCR Healthy lifestyle behaviors encompassing healthy eating and regular physical activity should be
recommended in all those with PCOS to achieve and/or maintain healthy weight and to optimize
hormonal outcomes, general health, and quality of life across the life course.
****
EBR Lifestyle intervention (preferably multicomponent including diet, exercise and behavioral strategies)
should be recommended in all those with PCOS and excess weight, for reductions in weight,
central obesity and insulin resistance.
***
44BB
CPP Achievable goals such as 5% to 10%weight loss in those with excess weight yields signiﬁcant clinical
improvements and is considered successful weight reduction within six months. Ongoing
assessment and monitoring is important during weight loss and maintenance in all women with
PCOS.
_
CPP SMART (Speciﬁc Measurable, Achievable, Realistic and Timely) goal setting and self-monitoring can
enable achievement of realistic lifestyle goals.
_
CPP Psychological factors such as anxiety and depressive symptoms, body image concerns and disordered
eating, need consideration and management to optimize engagement and adherence to lifestyle
interventions.
_
CPP Health professional interactions around healthy lifestyle, including diet and exercise, need to be
respectful, patient-centred and to value women's individualised healthy lifestyle preferences and
cultural, socioeconomic and ethnic differences. Health professionals need to also consider
personal sensitivities, marginalisation and potential weight-related stigma.
_
CPP Adolescent and ethnic-speciﬁc BMI and waist circumference categories need to be considered when
optimising lifestyle and weight.
_
CPP Healthy lifestyle may contribute to health and quality of life beneﬁts in the absence of weight loss. _
CPP Healthy lifestyle and optimal weight management appears equally effective in PCOS as in the general
population and is the joint responsibility of all health professionals, partnering with women with
PCOS. Where complex issues arise, referral to suitably trained allied health professionals needs to
be considered.
_
CPP Ethnic groups with PCOS who are at high cardiometabolic risk require greater consideration in terms
of healthy lifestyle and lifestyle intervention (see Ethnic Variation).
_
Behavioral strategies
CCR Lifestyle interventions could include behavioral strategies such as goal-setting, self-monitoring,
stimulus control, problem solving, assertiveness training, slower eating, reinforcing changes and
relapse prevention, to optimize weight management, healthy lifestyle and emotional wellbeing in
women with PCOS.
****
CPP Comprehensive health behavioral or cognitive behavioral interventions could be considered to
increase support, engagement, retention, adherence and maintenance of healthy lifestyle and
improve health outcomes in women with PCOS.
_
Dietary intervention
CCR A variety of balanced dietary approaches could be recommended to reduce dietary energy intake and
induce weight loss in women with PCOS and overweight and obesity, as per general population
recommendations.
****
CCR General healthy eating principles should be followed for all women with PCOS across the life course,
as per general population recommendations.
****
CPP To achieve weight loss in those with excess weight, an energy deﬁcit of 30% or 500-750 kcal/day
(1,200 to 1,500 kcal/day) could be prescribed for women, also considering individual energy
requirements, body weight and physical activity levels.
_
CPP In women with PCOS, there is no or limited evidence that any speciﬁc energy equivalent diet type is
better than another, or that there is any differential response to weight management intervention,
compared to women without PCOS.
_
CPP Tailoring of dietary changes to food preferences, allowing for a ﬂexible and individual approach to
reducing energy intake and avoiding unduly restrictive and nutritionally unbalanced diets, are
important, as per general population recommendations.
_
Exercise intervention
CCR Health professionals should encourage and advise the following for prevention of weight gain and
maintenance of health:
 In adults from 18 – 64 years, a minimum of 150 min/week of moderate intensity physical activity
or 75 min/week of vigorous intensities or an equivalent combination of both, including muscle
strengthening activities on 2 non-consecutive days/week
***
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 In adolescents, at least 60 minutes of moderate to vigorous intensity physical activity/day,
including those that strengthen muscle and bone at least 3 times weekly
 Activity be performed in at least 10-minute bouts or around 1000 steps, aiming to achieve at
least 30 minutes daily on most days.
CCR Health professionals should encourage and advise the following for modest weight-loss, prevention of
weight-regain and greater health beneﬁts:
 A minimum of 250 min/week of moderate intensity activities or 150 min/week of vigorous in-
tensity or an equivalent combination of both, and muscle strengthening activities involving
major muscle groups on 2 non-consecutive days/week
 Minimized sedentary, screen, or sitting time.
***
CPP Physical activity includes leisure time physical activity, transportation such as walking or cycling,
occupational work, household chores, games, sports or planned exercise, in the context of daily,
family and community activities. Daily, 10000 steps is ideal, including activities of daily living and
30 minutes of structured physical activity or around 3000 steps. Structuring of recommended
activities need to consider women's and family routines as well as cultural preferences
_
CPP Realistic physical activity SMART (Speciﬁc, Measureable, Achievable, Relevant, Time limited) goals
could include 10 minute bouts, progressively increasing physical activity 5% weekly, up to and
above recommendations.
_
CPP Self-monitoring including with ﬁtness tracking devices and technologies for step count and exercise
intensity, could be used as an adjunct to support and promote active lifestyles and minimize
sedentary behaviors.
_
Obesity and weight assessment
CCR Health professionals andwomen should be aware that womenwith PCOS have a higher prevalence of
weight gain and obesity, presenting signiﬁcant concerns for women, impacting on health and
emotional wellbeing, with a clear need for prevention.
***
CCR All those with PCOS should be offered regular monitoring for weight changes and excess weight (see
Cardiovascular Disease Risk).
****
CPP When assessing weight, related stigma, negative body image and/or low self-esteem need to be
considered and assessment needs to be respectful and considerate. Beforehand, explanations on
the purpose and how the information will be used and the opportunity for questions and
preferences needs to be provided, permission sought and scales and tape measures adequate.
Implications of results need to be explained and where this impacts on emotional wellbeing,
support provided.
_
CPP Prevention of weight gain,monitoring of weight and encouraging evidence-based and socio-culturally
appropriate healthy lifestyle is important in PCOS, particularly from adolescence.
_
4. PHARMACOLOGICAL TREATMENT FOR NON-FERTILITY INDICATIONS
Pharmacological treatment principles in PCOS
CPP Consideration of the individual's personal characteristics, preferences and values is important in
recommending pharmacological treatment.
_
CPP When prescribing pharmacological therapy in PCOS, beneﬁts, adverse effects and contraindications in
PCOS and general populations need to be considered and discussed before commencement.
_
CPP COCPs, metformin and other pharmacological treatments are generally off label# in PCOS. However
off label use is predominantly evidence-based and is allowed in many countries. Where it is
allowed, health professionals need to inform women and discuss the evidence, possible concerns
and side effects of treatment.
_
CPP Holistic approaches are required and pharmacological therapy in PCOS needs to be considered
alongside education, lifestyle and other options including cosmetic therapy and counselling.
_
Combined oral contraceptive pills (COCPs)
EBR The COCP alone should be recommended in adult women with PCOS for management of
hyperandrogenism and/or irregular menstrual cycles.
****
44BB
EBR The COCP alone should be considered in adolescents with a clear diagnosis of PCOS for management
of clinical hyperandrogenism and/or irregular menstrual cycles.
***
44BB
EBR The COCP could be considered in adolescents who are deemed ‘‘at risk’’ but not yet diagnosed with
PCOS, for management of clinical hyperandrogenism and irregular menstrual cycles.
***
44BB
EBR Speciﬁc types or dose of progestins, estrogens or combinations of COCP cannot currently be
recommended in adults and adolescents with PCOS and practice should be informed by general
population guidelines.
***
44BB
CCR The 35 microgram ethinyloestradiol plus cyproterone acetate preparations should not be considered
ﬁrst line in PCOS as per general population guidelines, due to adverse effects including venous
thromboembolic risks.
*
CPP When prescribing COCPs in adults and adolescents with PCOS:
 Various COCP preparations have similar efﬁcacy in treating hirsutism
_
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 The lowest effective estrogen doses (such as 20-30 micrograms of ethinyloestradiol or equiva-
lent), and natural estrogen preparations are preferred, balancing efﬁcacy, metabolic risk proﬁle,
side effects, cost and availability
 The generally limited evidence on effects of COCPs in PCOS needs to be appreciated with
practice informed by general population guidelines (WHO Guidelines)
 The relative and absolute contraindications and side effects of COCPs need to be considered and
be the subject of individualized discussion
 PCOS speciﬁc risk factors such as high BMI, hyperlipidemia and hypertension need to be
considered.
Combined oral contraceptive pills in combination with metformin and/or anti-androgen pharmacological agents
EBR In combination with the COCP, metformin should be considered in women with PCOS for
management of metabolic features where COCP and lifestyle changes do not achieve desired
goals.
****
44BB
EBR In combination with the COCP, metformin could be considered in adolescents with PCOS and BMIR
25 kg/m2 where COCP and lifestyle changes do not achieve desired goals.
****
44BB
CPP In combination with the COCP, metformin may be most beneﬁcial in high metabolic risk groups
including those with diabetes risk factors, impaired glucose tolerance, or high-risk ethnic groups.
_
EBR In combination with the COCP, antiandrogens should only be considered in PCOS to treat hirsutism,
after six months or more of COCP and cosmetic therapy have failed to adequately improve
symptoms.
**
44BB
CCR In combination with the COCP, antiandrogens could be considered for the treatment of androgen-
related alopecia in PCOS.
**
CPP In PCOS, antiandrogens must be used with effective contraception, to avoid male foetal
undervirilisation. Variable availability and regulatory status of these agents is notable and for some
agents, potential liver toxicity requires caution.
_
Metformin
EBR Metformin in addition to lifestyle, could be recommended in adult women with PCOS, for the
treatment of weight, hormonal, and metabolic outcomes.
***
44BB
EBR Metformin in addition to lifestyle, should be considered in adult women with PCOS with BMIR
25 kg/m2 for management of weight and metabolic outcomes.
***
44BB
EBR Metformin in additional to lifestyle, could be considered in adolescents with a clear diagnosis of PCOS
or with symptoms of PCOS before the diagnosis is made.
***
44BB
CPP Metformin may offer greater beneﬁt in high metabolic risk groups including those with diabetes risk
factors, impaired glucose tolerance or high-risk ethnic groups (see Ethnic variation)
_
CPP Where metformin is prescribed the following need to be considered:
 Adverse effects, including gastrointestinal side-effects that are generally dose dependent and
self-limiting, need to be the subject of individualized discussion
 Starting at a low dose, with 500 mg increments 1-2 weekly and extended release preparations
may minimize side effects
 Metformin use appears safe long-term, based on use in other populations, however ongoing
requirement needs to be considered and use may be associated with low vitamin B12 levels
 Use is generally off label and health professionals need to inform women and discuss the evi-
dence, possible concerns and side effects.
_
Anti-obesity pharmacological agents
CCR Anti-obesity medications in addition to lifestyle, could be considered for themanagement of obesity in
adults with PCOS after lifestyle intervention, as per general population recommendations.
_
CPP For anti-obesity medications, cost, contraindications, side effects, variable availability and regulatory
status need to be considered and pregnancy needs to be avoided whilst taking these medications.
_
Anti-androgen pharmacological agents
EBR Where COCPs are contraindicated or poorly tolerated, in the presence of other effective forms of
contraception, anti-androgens could be considered to treat hirsutism and androgen-related
alopecia.
***
4BBB
CPP Speciﬁc types or doses of anti-androgens cannot currently be recommended with inadequate
evidence in PCOS.
_
Inositol
EBR Inositol (in any form) should currently be considered an experimental therapy in PCOS, with emerging
evidence on efﬁcacy highlighting the need for further research.
*
4BBB
CPP Women taking inositol and other complementary therapies are encouraged to advise their health
professional.
_
5. ASSESSMENT AND TREATMENT OF INFERTILITY
Assessment of factors that may affect fertility, treatment response, or pregnancy outcomes
CPP Factors such as blood glucose, weight, blood pressure, smoking, alcohol, diet, exercise, sleep and
mental, emotional and sexual health need to be optimized in women with PCOS, to improve
_
Teede. International evidence-based guideline. Fertil Steril 2018.
374 VOL. 110 NO. 3 / AUGUST 2018
ASRM PAGES
TABLE 3
Continued.
Category (see Table 1
for deﬁnition) Recommendation
GRADE and
Quality
reproductive and obstetric outcomes, aligned with recommendations in the general population.
Refer to Lifestyle, Emotional Wellbeing and Diabetes risk sections.
CPP Monitoring during pregnancy is important in women with PCOS, given increased risk of adverse
maternal and offspring outcomes.
_
CCR In women with PCOS and infertility due to anovulation alone with normal semen analysis, the risks,
beneﬁts, costs and timing of tubal patency testing should be discussed on an individual basis.
***
CCR Tubal patency testing should be considered prior to ovulation induction in women with PCOS where
there is suspected tubal infertility.
***
Ovulation induction principles
CPP The use of ovulation induction agents, including letrozole, metformin and clomiphene citrate is off
label in many countries. Where off label use of ovulation induction agents is allowed, health
professionals need to inform women and discuss the evidence, possible concerns and side effects.
_
CPP Pregnancy needs to be excluded prior to ovulation induction. _
CPP Unsuccessful, prolonged use of ovulation induction agents need to be avoided, due to poor success
rates.
_
Letrozole
EBR Letrozole should be considered ﬁrst line pharmacological treatment for ovulation induction in women
with PCOS with anovulatory infertility and no other infertility factors to improve ovulation,
pregnancy and live birth rates.
****
44BB
CPP Where letrozole is not available or use is not permitted or cost is prohibitive, health professionals can
use other ovulation induction agents.
_
CPP Health professionals and women need to be aware that the risk of multiple pregnancy appears to be
less with letrozole, compared to clomiphene citrate.
_
Clomiphene citrate and metformin
EBR Clomiphene citrate could be used alone in womenwith PCOSwith anovulatory infertility and no other
infertility factors to improve ovulation and pregnancy rates.
***
4BBB
EBR Metformin could be used alone in women with PCOS, with anovulatory infertility and no other
infertility factors, to improve ovulation, pregnancy and live birth rates, although women should be
informed that there are more effective ovulation induction agents.
***
444B
EBR Clomiphene citrate could be used in preference, when considering clomiphene citrate or metformin
for ovulation induction in women with PCOSwho are obese (BMI isR 30 kg/m2) with anovulatory
infertility and no other infertility factors.
***
44BB
EBR If metformin is being used for ovulation induction in women with PCOS who are obese (BMIR
30 kg/m2) with anovulatory infertility and no other infertility factors, clomiphene citrate could be
added to improve ovulation, pregnancy and live birth rates.
***
44BB
EBR Clomiphene citrate could be combinedwith metformin, rather than persisting with clomiphene citrate
alone, in women with PCOS who are clomiphene citrate-resistant, with anovulatory infertility and
no other infertility factors, to improve ovulation and pregnancy rates.
***
44BB
CPP The risk of multiple pregnancies is increased with clomiphene citrate use and therefore monitoring
needs to be considered.
_
Gonadotrophins
EBR Gonadotrophins could be used as second line pharmacological agents in womenwith PCOSwho have
failed ﬁrst line oral ovulation induction therapy and are anovulatory and infertile, with no other
infertility factors.
***
44BB
EBR Gonadotrophins could be considered as ﬁrst line treatment, in the presence of ultrasoundmonitoring,
following counselling on cost and potential risk of multiple pregnancy, in women with PCOS with
anovulatory infertility and no other infertility factors.
***
44BB
EBR Gonadotrophins, where available and affordable, should be used in preference to clomiphene citrate
combined with metformin therapy for ovulation induction, in women with PCOS with anovulatory
infertility, clomiphene citrate-resistance and no other infertility factors, to improve ovulation,
pregnancy and live birth rates.
****
444B
EBR Gonadotrophins with the addition of metformin could be used rather than gonadotrophin alone, in
women with PCOS with anovulatory infertility, clomiphene citrate-resistance and no other
infertility factors, to improve ovulation, pregnancy and live birth rates.
***
444B
EBR Either gonadotrophins or laparoscopic ovarian surgery could be used in women with PCOS with
anovulatory infertility, clomiphene citrate-resistance and no other infertility factors, following
counselling on beneﬁts and risks of each therapy.
****
444B
CPP Where gonadotrophins are prescribed, considerations include:
 Cost and availability
 Expertise required for use in ovulation induction
 Degree of intensive ultrasound monitoring required
 Lack of difference in clinical efﬁcacy of available gonadotrophin preparations
 Low dose gonadotrophin protocols optimize monofollicular development
 Risk and implications of potential multiple pregnancy
_
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CPP Gonadotrophin induced ovulation is only triggered when there are fewer than three mature follicles
and needs to be cancelled if there are more than two mature follicles with the patient advised to
avoid unprotected intercourse.
_
Anti-obesity pharmacological agents
CCR Pharmacological anti-obesity agents should be considered an experimental therapy in women with
PCOS for the purpose of improving fertility, with risk to beneﬁt ratios currently too uncertain to
advocate this as fertility therapy.
*
Laparoscopic surgery
EBR Laparoscopic ovarian surgery could be second line therapy for women with PCOS, who are
clomiphene citrate resistant, with anovulatory infertility and no other infertility factors.
***
44BB
CCR Laparoscopic ovarian surgery could potentially be offered as ﬁrst line treatment if laparoscopy is
indicated for another reason in women with PCOS with anovulatory infertility and no other
infertility factors.
***
CPP Risks need to be explained to all women with PCOS considering laparoscopic ovarian surgery. _
CPP Where laparoscopic ovarian surgery is to be recommended, the following need to be considered:
 Comparative cost
 Expertise required for use in ovulation induction
 Intra-operative and post-operative risks are higher in women who are overweight and obese
 There may be a small associated risk of lower ovarian reserve or loss of ovarian function
 Periadnexal adhesion formation may be an associated risk.
_
Bariatric surgery
CCR Bariatric surgery should be considered an experimental therapy in women with PCOS, for the purpose
of having a healthy baby, with risk to beneﬁt ratios currently too uncertain to advocate this as
fertility therapy.
*
CPP If bariatric surgery is to be prescribed, the following need to be considered:
 Comparative cost
 The need for a structured weight management program involving diet, physical activity and
interventions to improve psychological, musculoskeletal and cardiovascular health to continue
post-operatively
 Perinatal risks such as small for gestational age, premature delivery, possibly increased infant
mortality
 Potential beneﬁts such as reduced incidence of large for gestational age fetus and gestational
diabetes
 Recommendations for pregnancy avoidance during periods of rapid weight loss and for at least
12 months after bariatric surgery with appropriate contraception.
If pregnancy occurs, the following need to be considered:
 Awareness and preventative management of pre-and post-operative nutritional deﬁciencies is
important, ideally in a specialist interdisciplinary care setting
 Monitoring of fetal growth during pregnancy.
_
In vitro fertilization (IVF)
CCR In the absence of an absolute indication for IVF intracytoplasmic sperm injection (ICSI), women with
PCOS and anovulatory infertility could be offered IVF as third line therapy where ﬁrst or second line
ovulation induction therapies have failed.
***
CPP In women with anovulatory PCOS, the use of IVF is effective and when elective single embryo transfer
is used, multiple pregnancies can be minimized.
_
CPP Women with PCOS undergoing IVF  ICSI therapy need to be counselled prior to starting treatment
including on:
 Availability, cost and convenience
 Increased risk of ovarian hyperstimulation syndrome
 Options to reduce the risk of ovarian hyperstimulation.
_
CCR Urinary or recombinant follicle stimulation hormone can be used in women with PCOS undergoing
controlled ovarian hyperstimulation for IVF  ICSI, with insufﬁcient evidence to recommend
speciﬁc follicle stimulating hormone (FSH) preparations.
_
CCR Exogenous recombinant luteinizing hormone treatment should not be routinely used in combination
with follicle stimulating hormone therapy in women with PCOS undergoing controlled ovarian
hyperstimulation for IVF  ICSI.
_
EBR A gonadotrophin releasing hormone antagonist protocol is preferred in women with PCOS
undergoing an IVF ICSI cycle, over a gonadotrophin releasing hormone agonist long protocol, to
reduce the duration of stimulation, total gonadotrophin dose and incidence of ovarian
hyperstimulation syndrome (OHSS).
***
44BB
CPP Human chorionic gonadotrophins is best used at the lowest doses to trigger ﬁnal oocyte maturation in
women with PCOS undergoing an IVF  ICSI cycle to reduce the incidence of OHSS.
_
CPP Triggering ﬁnal oocyte maturation with a gonadotropin-releasing hormone (GnRH) agonist and
freezing all suitable embryos could be considered in women with PCOS having an IVF/ICSI cycle
_
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with a GnRH antagonist protocol and at an increased risk of developing OHSS or where fresh
embryo transfer is not planned.
CPP In IVF  ICSI cycles in women with PCOS, consideration needs to be given to an elective freeze of all
embryos.
_
EBR Adjunct metformin therapy could be used before and/or during follicle stimulating hormone ovarian
stimulation in women with PCOS undergoing a IVF  ICSI therapy with a GnRH agonist protocol,
to improve the clinical pregnancy rate and reduce the risk of OHSS.
***
44BB
CCR In a GnRH agonist protocol with adjunct metformin therapy, in women with PCOS undergoing IVF 
ICSI treatment, the following could be considered:
 Metformin commencement at the start of GnRH agonist treatment
 Metformin use at a dose of between 1000 mg to 2550 mg daily
 Metformin cessation at the time of the pregnancy test or menses (unless the metformin therapy
is otherwise indicated)
 Metformin side-effects (see metformin section in this table)
_
CPP In IVF ICSI cycles, womenwith PCOS could be counselled on potential beneﬁts of adjunct metformin
in a GnRH antagonist protocol to reduce risk of ovarian hyperstimulation syndrome (see above for
metformin therapy considerations).
_
CPP The term in vitro maturation (IVM) treatment cycle is applied to ‘‘the maturation in vitro of immature
cumulus oocyte complexes collected from antral follicles’’ (encompassing both stimulated and
unstimulated cycles, but without the use of a human gonadotrophin trigger).
_
CCR In units with sufﬁcient expertise, IVM could be offered to achieve pregnancy and livebirth rates
approaching those of standard IVF  ICSI treatment without the risk of OHSS for women with
PCOS, where an embryo is generated, then vitriﬁed and thawed and transferred in a subsequent
cycle.
**
Note: EBR ¼ evidence based recommendation; CCR ¼ clinical consensus recommendation; CPP ¼ clinical practice point. Evidence quality:4444 ¼ high quality,
444B¼moderate quality,44BB¼ low quality and4BBB¼ very low quality evidence. **** Strong recommendation for the option; ***conditional recom-
mendation for the option; **conditional recommendation for either the option or the comparison; *conditional recommendation against the option. #Off-label pre-
scribing occurs when a drug is prescribed for an indication, a route of administration, or a patient group that is not included in the approved product information
document for that drug by the regulatory body. Prescribing off-label is often unavoidable and common and does not mean that the regulatory body has rejected
the indication, but more commonly there has not been a submission to request evaluation of the indication or that patient group for any given drug.
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ASRM PAGES European Society for Paediatric Endocrinology (ESPE)
 Exercise and Sports Science Australia (ESSA)
 Federation of Obstetric and Gynaecological Societies of
India (FOGSI)
 Fertility Society Australia (FSA)
 International Society of Endocrinology (ISE)
 International Federation of Fertility Societies (IFFS)
 International FederationofGynecology andObstetrics (FIGO)
 Italian Society of Gynaecology and Obstetrics
 Japanese Society for Paediatric Endocrinology (JSPE)
 Latin American Society for Paediatric Endocrinology
(SLEP)
 Nordic Federation of Societies of Obstetrics and Gynae-
cology (NFOG)
 PCOS Challenge
 PCOS Society of India
 Paediatric Endocrine Society (PES)
 Polycystic Ovary Association Australia (POSSA)
 Royal Australasian College of Physicians (RACP)
 Royal Australian College of General Practitioners (RACGP)
 Royal Australian and New Zealand College of Obstetri-
cians and Gynaecologists (RANZCOG)
 Royal College of Obstetricians and Gynaecologists (RCOG)
 South African Society of Gynaecology and Obstetrics
(SASOG)
 Verity UK
 Victorian Assisted Reproductive Technology Associa-
tion (VARTA)
Other relevant organizations are welcome to partner in
guideline translation once approved.AUTHORS’ ROLES
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